InflammX Therapeutics Announces Option Agreement with Bausch + Lomb
1. Bausch + Lomb secured an option to acquire InflammX Therapeutics. 2. InflammX develops therapies for retinal diseases, targeting unmet medical needs. 3. The pipeline includes a candidate for intermediate age-related macular degeneration. 4. The agreement could enhance BHC's innovation-driven retinal portfolio. 5. Thierry Hashad sees potential in combining resources for retinal disease treatment.